脂肪原/含脂肪素A/AG-CN2-0490-M001/1毫克
商品编号：
AG-CN2-0490-M001
品牌：
Adipogen Inc
市场价：
¥1400.00
美元价：
840.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | NSC 101088; NSC 273757; 5β,6β-Epoxy-4β,22R,27-trihydroxy-1-oxo-δ-lactone-ergosta-2,24-dien-26-oic acid |
| Product Type | Chemical |
| Properties | |
| Formula | C28H38O6 |
| MW | 470.6 |
| Merck Index | 14: 10048 |
| CAS | 5119-48-2 |
| RTECS | KE7288500 |
| Source/Host Chemicals | Isolated from Withania somnifera. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO (10mg/ml), DMF, 100% ethanol (5mg/ml), methanol (5mg/ml) or ethyl acetate. Insoluble in water. |
| InChi Key | DBRXOUCRJQVYJQ-KUVJLYTASA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light when in solution. |
| Use/Stability |
Stable for at least 2 years after receipt when stored at -20°C. Stock solutions are stable for at least 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Multifunctional anticancer compound. Amplifies the cellular antioxidant and/or detoxification system, suppresses inflammatory pathways, selectively inhibits tumor cell proliferation and induces apoptosis, suppresses tumor angiogenesis, blocks epithelial-to-mesenchymal transition (EMT), tumor invasion and metastasis, alters tumor cell metabolism, induces immunomodulation and downregulates cancer stem cells targets.
- Sensitizes resistant cancer cells to existing chemotherapeutic agents.
- Antioxidant. Induces cytoprotective enzymes (Nrf2-dependent as well), including SOD, HO-1 (heme oxygenase-1), catalase, glutathione peroxidise, glutathione s-transferase and NQO1.
- Anti-inflammatory agent. Inhibits COX-2 and iNOS expression (at protein and mRNA level) and PGE2 production. Prevents NF-κB activation by inhibiting activation of IKKβ. Inhibits Helicobacter pylori-induced IL-1β production by regulating NF-κB and directly inhibiting NLRP3 inflammasome activation.
- Antiproliferative agent. Induces G2/M phase cell cycle arrest, targeting CDKs. Shown to modulate STAT3, Bcl2, Notch receptors, Akt, Hsp90, EGFR, HER2 and PCNA.
- Disrupts the organization of microtubules and actin/microfilament. Stimulates F-actin cross-linking.
- Induces tumor cell apoptosis. Shown to induce ROS production. Activates mitochondrial apoptosis pathway through Bcl-2 downregulation and Bax upregulation. Shown to induce p53-dependent pathways and ER-stress. Activates the tumor suppressor protein PAR-4. Directly or indirectly inhibits selected other kinases, such MAPK or STAT3. Shown to inhibit hedgehog signalling pathway.
- Described to be an autophagy inducer and inhibitor.
- Potent inhibitor of the 20S proteasome β5 subunit chymotrypsin-like activity.
- Potent angiogenesis inhibitor by modulating VEGF. Antimigratory, antiinvasive and antimetastatic compound. Targets TGF-β, vimentin, MMPs and Notch receptors.
- Inhibits cancer stem cells targets, including aldehyde dehydrogenase 1 (ALDH1) activity. Alters cell line-specific the mRNA expression of cancer stem cell markers, such as Oct4, SOX-2, and Nanog.
- Reported to induce neuronal regeneration.
- Antidiabetic compound. Potent Leptin sensitizer, acting similar to Celastrol (Prod. No. AG-CN2-0460).
Product References
- Antitumor activity of withaferin A (NSC-101088): B. Shohat, et al.; Cancer Chemother. Rep. 51, 271 (1967)
- Withaferin A is a potent inhibitor of angiogenesis: R. Mohan, et al.; Angiogenesis 7, 115 (2004)
- Neuritic regeneration and synaptic reconstruction induced by withanolide: A: T. Kuboyama, et al.; Br. J. Pharmacol. 144, 961 (2005)
- The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry": H. Yang, et al.; Mol. Pharmacol. 71, 426 (2007)
- The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin: P. Bargagna-Mohan, etal.; Chem. Biol. 14, 623 (2007)
- Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade: C. Mandal, et al.; Apoptosis 13, 1450 (2008)
- Inhibition of monosodium urate crystal-induced inflammation by withaferin A: E.P. Sabina, et al.; J. Pharm. Pharm. Sci. 11, 46 (2008)
- Withaferin A targets heat shock protein 90 in pancreatic cancer cells: Y. Yu, et al.; Biochem. Pharmacol. 79, 542 (2010)
- Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis: S. Koduru, et al.; Mol. Cancer Ther. 9, 202 (2010)
- Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells: J. Lee, et al.; Carcinogenesis. 31, 1991 (2010)
- Inhibition of the NEMO/IKKß association complex formation, a novel mechanism associated with the NF-kB activation suppression by Withania somnifera's key metabolite withaferin A: A. Grover, et al.; BMC Genomics 11, s25 (2010)
- Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2: E. Mayola, et al.; Apoptosis 16, 1014 (2011)
- Withaferin a alters intermediate filament organization, cell shape and behavior: B. Grin, et al.; PLoS One 7, e39065 (2012)
- Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells: J. Lee, et al.; Breast Cancer Res. Treat. 136, 45 (2012)
- Molecular insight in the multifunctional activities of Withaferin A: W. Van den Berghe, et al.; Biochem. Pharmacol. 84, 1282 (2012) (Review)
- Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera's key metabolite Withaferin A: S. Saha, et al.; In Silico Pharmacol. 1, 11 (2013)
- Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKß: K. Heyninck, et al.; Biochem. Pharmacol. 91, 501 (2014)
- Withaferin A Inhibits Helicobacter pylori-induced Production of IL-1β in Dendritic Cells by Regulating NF-κB and NLRP3 Inflammasome Activation: J.E. Kim, et al.; Immune Netw. 15, 269 (2015)
- Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase: S.V. Reddy, et al.; J. Biomol. Struct. Dyn. 33, 2695 (2015)
- Hedgehog inhibitors from Withania somnifera: T. Yoneyama, et al.; Bioorg. Med. Chem. Lett. 25, 3541 (2015)
- The Use of Withaferin A to study intermediate filaments: R. Mohan & P. Bargagna-Mohan; Methods Enzymol. 568, 187 (2016)
- Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells: Autophagy 12, 1521 (2016)
- Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice: J. Lee, et al.; Nat. Med. 22, 1023 (2016)
- Withaferin-A - A natural anticancer agent with pleitropic mechanisms of action: I.C. Lee & B.Y. Choi; Int. J. Mol. Sci. 17, 290 (2016) (Review)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
